A Phase II trial of suramin monthly × 3 for hormone‐refractory prostate carcinoma

The goal of the current study was to determine the prostate‐specific antigen (PSA) and objective response rates and the pharmacokinetics associated with a monthly × 3 one‐hour infusion of suramin in 58 patients with hormone‐refractory prostate carcinoma.

[1]  O. Sartor,et al.  Suramin's Development: What Did we Learn? , 2002, Investigational New Drugs.

[2]  G. Rosner,et al.  Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Ratain,et al.  A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer , 2002, Cancer Chemotherapy and Pharmacology.

[4]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[5]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[6]  J. de Irala,et al.  Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma , 2001, Cancer.

[7]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[8]  E. Small,et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Small,et al.  Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Meyers,et al.  Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Lake,et al.  A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma , 2000, Cancer.

[12]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Small,et al.  Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Ratain,et al.  Mineralocorticoid insufficiency due to suramin therapy , 1996, Cancer.

[16]  A. Belldegrun,et al.  Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Jodrell,et al.  Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L Janish,et al.  Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Scher,et al.  Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. R. Cooper,et al.  Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.

[21]  P. Schellhammer,et al.  Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. , 1995, Urology.

[22]  C. Stein,et al.  Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.

[23]  H. Scher.  Suramin: here to stay!? , 1993, Journal of the National Cancer Institute.

[24]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Heimans,et al.  Suramin: rapid loading and weekly maintenance regimens for cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Steinberg,et al.  Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Lelièvre,et al.  Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Denis,et al.  Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease. , 1990, European journal of cancer.

[29]  C. Hensey,et al.  Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A , 1989, FEBS letters.

[30]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[31]  C. Heldin,et al.  Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Hosang.  Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.

[33]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[34]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .